Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
Welcome to Medicare Part D, where your prescription drugs come with co-pays and co-insurance. If you thought co-pays and ...
Bristol Myers Squibb and Alexandria Real Estate are top picks for the income-focused, offering high dividends and growth ...
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...
Shares of Pfizer (NYSE: PFE), and UnitedHealth Group (NYSE: UNH) have been beaten down to near 52-week lows. Shares of Pfizer ...
Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...
Summary Apixaban is an oral ... regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...
Zacks.com on MSN2d
Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback